About

Professor Tanja Fehm is a leading figure in gynecologic oncology, with a research focus sharpened on the clinical behavior and optimal management of borderline ovarian tumors (BOT). Her major contributions stem from her pivotal role in the large-scale AGO ROBOT study, which has fundamentally shaped the understanding of this disease. Her work has demonstrated that age is a critical variable in BOT prognosis, revealing that younger patients often present with distinct clinical characteristics and outcomes. Furthermore, she has rigorously analyzed the prognostic impact of individual surgical staging procedures, providing evidence-based guidance for treatment. Her most cited paper, an analysis of age-dependent differences in BOT, has garnered 75 citations, underscoring its influence. Beyond BOT, Professor Fehm has contributed to the critical discourse on cervical cancer treatment, notably through her commentary on the landmark LACC trial. Her research, which also includes evaluating the diagnostic value of serum CA125, has been instrumental in refining surgical and diagnostic strategies, directly impacting patient care and establishing her as a key authority in her field.

Research Focus

Key Achievements

4
H-Index
4
Papers
148
Total Citations
37
Avg Citations/Paper
🏆 Most Cited Paper
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study
75 citations · 2014
📈 Most Prolific Year: 2015 (2 Papers)
🤝 Key Collaborators: 47
🏛 Institutions: Universitätsklinikum Tübingen, Institut für Frauengesundheit, Düsseldorf University Hospital, Imperial College London

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago